Transgene SA (EPA:TNG)
0.6180
-0.0060 (-0.97%)
Apr 28, 2025, 11:07 AM CET
Transgene Employees
Transgene had 144 employees as of December 31, 2024. The number of employees increased by 3 or 2.13% compared to the previous year.
Employees
144
Change (1Y)
3
Growth (1Y)
2.13%
Revenue / Employee
€44,118
Profits / Employee
€235,910
Market Cap
81.54M
Employees Chart
Related Stocks
Company Name | Employees |
---|---|
EssilorLuxottica Société anonyme | 153,498 |
Sanofi | 82,878 |
Sartorius Stedim Biotech | 9,901 |
bioMérieux | 14,754 |
Eurofins Scientific SE | 62,696 |
Ipsen | 5,358 |
Virbac | 5,620 |
emeis Société anonyme | 83,000 |
Transgene News
- 7 months ago - Half Year 2024 Transgene SA Earnings Call Transcript - GuruFocus
- 1 year ago - Transgene SA (TRGNF) Q2 2023 Earnings Call Transcript - Seeking Alpha
- 2 years ago - Transgene Announces New Leadership Structure to Accelerate the Development of its Innovative Immunotherapy Portfolio - Business Wire
- 2 years ago - Transgene Receives Approval to Start a Phase I Trial of TG6050, a Novel IL-12-Armed Oncolytic Virus Given by Intravenous Administration - Business Wire
- 2 years ago - Transgene and BioInvent Joint Paper on BT-001 Wins JITC “Best Oncolytic and Local Immunotherapy Paper” Award for 2022 - Business Wire
- 2 years ago - BioInvent and Transgene Joint Paper on BT-001 Wins JITC Best Oncolytic and Local Immunotherapy Paper Award for 2022 - Accesswire
- 2 years ago - Transgene Announces Positive Interim Analysis Results of Phase II Trial Evaluating TG4001 + Avelumab vs Avelumab in HPV-Positive Anogenital Cancers - Business Wire
- 2 years ago - R&D Day: Presentations to Highlight Transgene's Competitive Positioning, Capabilities to Engineer Novel Immunotherapies for Patients with Cancer, and Update on Initial Clinical Data - Business Wire